ReNAgade exists to unlock the potential for RNA medicines to treat disease anywhere in the body. We combine our novel RNA delivery platforms with a comprehensive RNA platform allowing for an all-RNA system for coding, editing and gene insertion to develop new medicines.To accelerate the future of medicine, we bring together a team with deep RNA and delivery expertise to develop paradigm-shifting RNA medicines. ReNAgade Therapeutics – RNA Without Limits

Scientist Molecular Biology

Research Associate Molecular Biology (Contract)

ReNAgade Therapeutics

Principal Research Associate

Senior Research Associate

Associate Scientist I

Lab Manager

Principal

Principal Scientist

Senior Scientist

Senior Director, People Experience and HR

Director, People Experience

Associate Director, People Experience

Human Resources Manager

Senior Human Resources Associate

Marketing and Recruiting Associate

Mezzo-soprano

Music and Movement Teacher/Assistant Teacher

Accounts Receivable

Associate Director

Associate Director in translational research

Staff Scientist

Research Professor

Postdoctoral Researcher

Director, Toxicology

Senior Principal Scientist, Toxicology

Associate Director, Toxicology

Senior Scientist, Toxicology

Scientist, Immunotoxicology and Investigative Toxicology

Scientist, Product Discovery

Scientist II

Scientist I

Associate Scientist, DMPK

Senior RA II, DMPK

Research Associate

Senior Research Associate, DMPK

Research Assistant

Research Associate II | Discovery Metabolomics

Business Development

Associate Scientist I - Intern

Chemical Engineer - Intern

Postdoctoral Research Associate

PhD student

Inspector

Principal Scientist, Delivery Chemistry

Scientist II, Non-Viral Delivery

Scientist, Non-Viral Delivery

Development Scientist

Biomedical Engineer (Externship)

Doctoral Candidate, Bioinnovation Fellow

Research Biochemist

Medicinal Chemistry Intern

Undergraduate Research Fellow

Research Associate in Next Generation Therapeutics and Automation

Amgen Scholar, Hagiwara Lab

Research Intern, Lindner Lab

Student Consultant

Mentor

Residential Counselor, Office of Engineering and Outreach Programs

Student Researcher, Chevrier Research Group

Research Fellow, Church Lab

Student Caller

Marketing and Outreach Intern

Student Researcher and Lab Assistant, Hildebrandt Lab

Summer Intern

Route 53

Mimecast

Outlook

Microsoft Office 365

WordPress.org

Google Tag Manager

CSO-Editing

Verve Therapeutics is a clinical-stage biotechnology company created with a singular focus: to protect the world from heart disease. Founded by world-leading experts in cardiovascular medicine, human genetics and gene editing, the company aims to develop transformative, once-and-done therapies for coronary heart disease. Verve's gene editing medicines are designed to safely edit the genome of adults and mimic naturally occurring gene variants to permanently lower LDL cholesterol and triglyceride levels. The company is advancing a pipeline of precision genetic medicines, led by VERVE-101, which is being developed initially for heterozygous familial hypercholesterolemia, a potentially fatal genetic heart disease. In 2023, Verve was recognized as a "Best Places to Work" by the Boston Globe. Verve is headquartered in Boston, Massachusetts.

Vice President, Analytical Development

Verve Therapeutics

WP Engine

Adobe Marketing Cloud

Varnish

VP Gene editing and Discovery

Spotlight Therapeutics is a venture funded early-stage biotechnology company with a mission to develop a new class of therapeutics by enabling direct in vivo gene editing. Founded by Alex Marson (UCSF), Jacob Corn (UC Berkeley), and Patrick Hsu (Salk Institute) in December of 2017, Spotlight is building its core technology platform to achieve precise in vivo gene editing in targeted cell populations. With a therapeutic focus centered on oncology, our engineered nucleases edit the genes in targeted disease organs thereby inactivating or altering the gene product. We are hiring rapidly to build out our cutting-edge research and development team.  This team is responsible for preclinical development ranging from protein engineering, gene editing to immuno-oncology and in vivo safety studies. Join us and work on the next generation of gene editing therapeutics in a fast-paced and exciting environment.

Spotlight Therapeutics

Gmail

Google Apps

Mobile Friendly

Typekit

Remote

Circle

VP Technology

What if you could repair broken genes? That is the question we ask ourselves every day at Editas Medicine. We're a clinical stage genome editing company focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cas12a genome editing systems into a robust pipeline of treatments for people living with serious diseases around the world. Our goal is to discover, develop, manufacture, and commercialize transformative, durable, precision genomic medicines for a broad class of diseases.We are a vibrant company full of hope, possibilities, and a belief that, working together as One Editas, we can truly revolutionize the development of medicines. We are on an important journey to unlock the full potential of genome editing technology. A journey fueled by our distinct culture, expert team of Editas Medicine ‘Editors', and the patients we aspire to help around the world. Connect with us to hear about the tremendous progress and scientific advancements we've already made and the next breakthrough on the horizon. If you are ingenious, passionate and resilient, come join the revolution. Repairing broken genes is only the beginning.

Scientist/Senior Scientist Histology and Imaging

Sr. Scientist II, In Vivo Therapeutics Discovery

Senior Manager, QA Technical Operations

Medical Director, Medical Affairs

Editas Medicine

Google Cloud Hosting

DNS Made Easy

GoDaddy Hosting

Google Analytics

Associate Director, Protein Engineering and Computational Biology

Senior Scientist, Computational Biology

In July 2021, MorphoSys acquired Constellation Pharmaceuticals. This transformational acquisition bolstered MorphoSys' position as a leader in hematology and oncology and marked the beginning of an important next chapter in the company's history.​MorphoSys' mission is more life for people with cancer. As a global commercial-stage biopharmaceutical company, MorphoSys uses groundbreaking science and technologies to discover, develop, and deliver innovative cancer medicines to patients. MorphoSys is headquartered in Planegg, Germany, and has its U.S. operations anchored in Boston, Massachusetts. ​Read more about the acquisition here: https://www.morphosys.com/media-investors/media-center/morphosys-to-complete-transformational-acquisition-of-constellation ​Learn more about MorphoSys: www.MorphoSys.com  ​

Hari Jayaram

CSO-Editing at ReNAgade Therapeutics

Hari Jayaram's Professional Contact Details

Hari Jayaram's Current Company Details

ReNAgade Therapeutics

Hari Jayaram's Work History and Education

Others Named Hari Jayaram

Frequently Asked Questions about Hari Jayaram

What company does Hari Jayaram work for?

What is Hari Jayaram's role at ReNAgade Therapeutics?

What is Hari Jayaram's email address?

What is Hari Jayaram's business email address?

What is Hari Jayaram's direct mobile number?

What is Hari Jayaram's HQ phone number?

What industry does Hari Jayaram work in?

Who are Hari Jayaram's colleagues?

Colleagues at ReNAgade Therapeutics

Prospect on LinkedIn

People Search

Company Search

Erik Straub

Michael Transon

Ready to try it out?